Home / Product /

Product

The company’s product is a microchip for detection of natural and adaptive immunoglobulins in blood/plasma of a patient and hardware-software system for data analysis.

Two versions of the microchip are available:

Microchip setup

Microchip is a plastic slide 25х75х>1 mm with about 600 immobilized ligands, namely:

 Results obtaining

The test is performed by application of serum or plasma sample onto the chip and revealing of immunoglobulins specific for a particular pathology using fluorescence labelled secondary antibodies (separately IgG and IgM). Protocol of analysis using microchip can be found here.

A special reader providing fluorescence detection of signals on microchip is used for recording the microchip results. Most part of commercially available devices is suitable for microchip analysis.

At first the results of the scanning are processed using the software included in the standard manufacturer’s package. Then obtained dataset are interpreted by specially designed software.

Microchip features

  • Analysis of one blood or plasma sample for the presence of several hundred of specific immunoglobulins this allowing revealing of about 100 pathologies using a single microchip. This feature considerably simplifies and decrease the cost of the test procedure for serum/plasma analysis;

  • Possibility of performing oncodiagnostics with the help of diagnostic signatures (combinations of several specific antibodies);

Comparison to ELISA:

  • Decreased percentage of erroneous false negative assay results due to inclusion of several versions of the same ligand in composition of microchip;

  • High sensitivity:

  1. high analytical sensitivity due to the use of fluorescent detection;

  2. exact determination of antibodies with both low and high titer (due to the broad dynamic range of the method);

  3. exact determination of high affinity antibodies.

  • Possibility of full automation of the assay process excluding human factor effect;

  • Possibility of performing retrospective analyses in future: at present many ligands are printed onto microchip for long term studies of antibodies of possible though not proven yet diagnostic significance. In future, after the obtaining of diagnostic status for the antibodies to these ligands it will be possible to make a diagnosis based on analyses performed earlier.

  • Possibility of total replacement of ELISA in the field of oncodiagnostics.


More info